Cost-Effectiveness of Betrixaban Compared with Enoxaparin for Venous Thromboembolism Prophylaxis in Nonsurgical Patients with Acute Medical Illness in the United States

被引：0
|
作者：
Holly Guy
Vicki Laskier
Mark Fisher
W. Richey Neuman
Iwona Bucior
Steven Deitelzweig
Alexander T. Cohen
机构：
[1] FIECON Ltd,
[2] Portola Pharmaceuticals,undefined
[3] Inc,undefined
[4] Ochsner Clinic Foundation and The University of Queensland School of Medicine,undefined
[5] Ochsner Clinical School,undefined
[6] Guy’s and St,undefined
[7] Thomas’ Hospitals,undefined
来源：
PharmacoEconomics | 2019年 / 37卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：701 / 714
页数：13
相关论文
共 50 条
  • [31] Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous thromboembolism in Canada
    Diamantopoulos, Alexander
    Lees, Michael
    Wells, Philip S.
    Forster, Fiona
    Ananthapavan, Jaithri
    McDonald, Heather
    [J]. THROMBOSIS AND HAEMOSTASIS, 2010, 104 (04) : 760 - 770
  • [32] Cost-Effectiveness of Venous Thromboembolism Prophylaxis After Hospitalization in Patients With Inflammatory Bowel Disease
    Lee, Kate E.
    Lim, Francesca
    Colombel, Jean-Frederic
    Hur, Chin
    Faye, Adam S.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2021, 116 : S384 - S385
  • [33] Cost-effectiveness of Venous Thromboembolism Prophylaxis After Hospitalization in Patients With Inflammatory Bowel Disease
    Lee, Kate E.
    Lim, Francesca
    Colombel, Jean-Frederic
    Hur, Chin
    Faye, Adam S.
    [J]. INFLAMMATORY BOWEL DISEASES, 2022, 28 (08) : 1169 - 1176
  • [34] Cost-effectiveness of venous thromboembolism prophylaxis after hospitalization in patients with Inflammatory Bowel Disease
    Lee, K.
    Lim, F.
    Colombel, J. F.
    Hur, C.
    Faye, A.
    [J]. JOURNAL OF CROHNS & COLITIS, 2021, 15 : S477 - S477
  • [35] The cost-effectiveness of extended venous thromboembolism prophylaxis with enoxaparin versus short-term prophylaxis after elective hip replacement in Poland
    Orlewska, E
    [J]. VALUE IN HEALTH, 2003, 6 (06) : 666 - 667
  • [36] COST-EFFECTIVENESS OF EXTENDED VENOUS THROMBOEMBOLISM PROPHYLAXIS AFTER RADICAL CYSTECTOMY
    Rydberg, Michael
    Park, Sangtae
    [J]. JOURNAL OF UROLOGY, 2016, 195 (04): : E619 - E619
  • [37] Cost-effectiveness of venous thromboembolism prophylaxis after total hip replacement
    Caprini, JA
    Arcelus, JL
    Kudrna, JC
    Sehgal, LR
    Oyslender, M
    Maksimovic, D
    MacDougall, A
    [J]. PHLEBOLOGY, 2002, 17 (3-4) : 126 - 133
  • [38] A Cost-Effectiveness Analysis of Fondaparinux Sodium Compared with Enoxaparin Sodium as Prophylaxis Against Venous ThromboembolismUse in Patients Undergoing Major Orthopaedic Surgery
    Sean D. Sullivan
    Bruce L. Davidson
    Susan R. Kahn
    James E. Muntz
    Gerry Oster
    Gary Raskob
    [J]. PharmacoEconomics, 2004, 22 : 605 - 620
  • [39] Venous thromboembolism prophylaxis in ambulatory cancer patients initiating chemotherapy: A cost-effectiveness analysis.
    Ryan, Emma
    Salinaro, Julia
    Havrilesky, Laura J.
    Davidson, Brittany Anne
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [40] Cost-effectiveness of pharmacological prophylaxis in preventing venous thromboembolism in patients undergoing hip fracture surgery
    Hitos, K.
    Stratton, C.
    Fletcher, J. P.
    [J]. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 2011, 9 : 903 - 903
12345